530 related articles for article (PubMed ID: 23370250)
1. Advances in targeting cell surface signalling molecules for immune modulation.
Yao S; Zhu Y; Chen L
Nat Rev Drug Discov; 2013 Feb; 12(2):130-46. PubMed ID: 23370250
[TBL] [Abstract][Full Text] [Related]
2. Targeting B cells with biologics in systemic lupus erythematosus.
La Cava A
Expert Opin Biol Ther; 2010 Nov; 10(11):1555-61. PubMed ID: 20919800
[TBL] [Abstract][Full Text] [Related]
3. Antibody internalization after cell surface antigen binding is critical for immunotoxin development.
Kuo SR; Alfano RW; Frankel AE; Liu JS
Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Immunobiological Therapies for Advanced Melanoma.
Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
[TBL] [Abstract][Full Text] [Related]
5. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
Tschernia NP; Gulley JL
BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
[TBL] [Abstract][Full Text] [Related]
6. Biological response modifiers may yield a new class of drugs to treat arthritis.
Skolnick AA
JAMA; 1997 Jan 22-29; 277(4):276-8. PubMed ID: 9002476
[No Abstract] [Full Text] [Related]
7. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
8. Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
Lipowska-Bhalla G; Fagnano E; Illidge TM; Cheadle EJ
Leuk Lymphoma; 2016; 57(6):1269-80. PubMed ID: 27050042
[TBL] [Abstract][Full Text] [Related]
9. Polymeric micro- and nanoparticles for immune modulation.
Ben-Akiva E; Est Witte S; Meyer RA; Rhodes KR; Green JJ
Biomater Sci; 2018 Dec; 7(1):14-30. PubMed ID: 30418444
[TBL] [Abstract][Full Text] [Related]
10. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
Battella S; Cox MC; Santoni A; Palmieri G
J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
De Felice F; Marchetti C; Palaia I; Musio D; Muzii L; Tombolini V; Panici PB
J Immunol Res; 2015; 2015():191832. PubMed ID: 26236750
[TBL] [Abstract][Full Text] [Related]
12. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
Stohl W
Curr Rheumatol Rep; 2012 Aug; 14(4):303-9. PubMed ID: 22547203
[TBL] [Abstract][Full Text] [Related]
13. Immune signatures predicting responses to immunomodulatory antibody therapy.
Pawelec G
Curr Opin Immunol; 2018 Apr; 51():91-96. PubMed ID: 29550661
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
Schifferli A; Nimmerjahn F; Kühne T
Front Immunol; 2019; 10():1196. PubMed ID: 31214173
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapies: what and when?
Johnston SL
J Clin Pathol; 2007 Jan; 60(1):8-17. PubMed ID: 17213345
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.
Flynn MJ; Hartley JA
Br J Haematol; 2017 Oct; 179(1):20-35. PubMed ID: 28556984
[TBL] [Abstract][Full Text] [Related]
17. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
Sibilia J
Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
19. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Agents in Follicular Lymphoma.
Ysebaert L; Morschhauser F
Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
